

Melanie R Nicol

List of Publications by Citations

Source: <https://exaly.com/author-pdf/245622/melanie-r-nicol-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

1,818
citations

16
h-index

41
g-index

41
ext. papers

2,312
ext. citations

6.3
avg, IF

4.8
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 40 | A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 517-525 | 59.2 | 803 |
| 39 | Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 623-631 | 8 | 298 |
| 38 | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa130 | 1 | 122 |
| 37 | Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. <i>Open Forum Infectious Diseases</i> , | 1 | 78 |
| 36 | Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021 , 72, e835-e843 | 11.6 | 59 |
| 35 | RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 11086-91 | 11.5 | 56 |
| 34 | Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, 843-851 | 25.5 | 51 |
| 33 | Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 574-83 | 2.9 | 38 |
| 32 | Pharmacogenomics of COVID-19 therapies. <i>Npj Genomic Medicine</i> , 2020 , 5, 35 | 6.2 | 36 |
| 31 | Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 766-769 | 6.1 | 34 |
| 30 | Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500 | 1 | 26 |
| 29 | Pharmacologic opportunities for HIV prevention. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 598-609 | 6.1 | 24 |
| 28 | Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 809-22 | 6.2 | 19 |
| 27 | A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19-A Call for Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa350 | 1 | 19 |
| 26 | Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial 2020 , | | 17 |
| 25 | Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1135-1149 | 6.1 | 17 |
| 24 | Models for predicting effective HIV chemoprevention in women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 68, 369-76 | 3.1 | 16 |

| | | | |
|----|---|------|----|
| 23 | Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64, | 5.9 | 14 |
| 22 | HIV PrEP Trials: The Road to Success. <i>Clinical Investigation</i> , 2013 , 3, | | 13 |
| 21 | Short communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 1058-64 | 1.6 | 12 |
| 20 | Minimum Inhibitory Concentration Distribution of Fluconazole against <i>Cryptococcus</i> Species and the Fluconazole Exposure Prediction Model. <i>Open Forum Infectious Diseases</i> , 2019 , 6, | 1 | 10 |
| 19 | Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. <i>Pharmacotherapy</i> , 2019 , 39, 486-500 | 5.8 | 10 |
| 18 | Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 2020 , | | 8 |
| 17 | Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1381-1395 | 2.9 | 7 |
| 16 | Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz478 | 1 | 7 |
| 15 | Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1717-1724 | 11.6 | 7 |
| 14 | The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. <i>Aids</i> , 2018 , 32, 11-15 | 3.5 | 5 |
| 13 | Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis. <i>Clinical and Translational Science</i> , 2019 , 12, 445-449 | 4.9 | 4 |
| 12 | Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019 , 46, 565-576 | 2.7 | 2 |
| 11 | Reply to Neves. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1772-e1774 | 11.6 | 2 |
| 10 | Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda. <i>BMC Infectious Diseases</i> , 2020 , 20, 572 | 4 | 2 |
| 9 | Endogenous Hormones and Antiretroviral Exposure in Plasma, Cervicovaginal Fluid, and Upper-Layer Packed Cells of Malawian Women Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 641-646 | 1.6 | 1 |
| 8 | Treating viruses in the brain: Perspectives from NeuroAIDS. <i>Neuroscience Letters</i> , 2021 , 748, 135691 | 3.3 | 1 |
| 7 | Short Communication: A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. <i>AIDS Research and Human Retroviruses</i> , 2021 , 37, 529-533 | 1.6 | 0 |
| 6 | Oral Maraviroc and Tenofovir for HIV Prevention in Women: An Ex Vivo and Translational Approach. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A58-A58 | 1.6 | |

| | | |
|---|--|-----|
| 5 | Rates of refusal of clinical autopsies among HIV-positive decedents and an overview of autopsies in Uganda. <i>Wellcome Open Research</i> , 6, 302 | 4.8 |
| 4 | Rates of refusal of clinical autopsies among HIV-positive decedents and an overview of autopsies in Uganda.. <i>Wellcome Open Research</i> , 2021, 6, 302 | 4.8 |
| 3 | Case Report: ThreeWa crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. <i>Wellcome Open Research</i> , 2018, 3, 111 | 4.8 |
| 2 | 88462 Fluconazole distribution in CNS and gynecological tissues in HIV-related cryptococcal meningitis decedents. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 96-96 | 0.4 |
| 1 | Case Report: ThreeWa crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. <i>Wellcome Open Research</i> , 2018, 3, 111 | 4.8 |